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Systemic sclerosisAbstract Aim of the work: To measure the extent of subclinical atherosclerosis in patients with
systemic sclerosis, and to evaluate any potential vascular risk factors in these patients.
Patients and methods: This study included 30 patients with systemic sclerosis diagnosed accord-
ing to the American college of rheumatology criteria and 20 healthy individuals were also included
as a control group. Non-invasive vascular tests including; carotid duplex scanning measuring com-
mon carotid arteries (CCA) intima-media thickness (IMT), and ankle brachial pressure index
(ABPI) were performed. Traditional vascular risk factors such as blood pressure, blood sugar, lipid
proﬁles, steroid usage and other immunosuppressive medications were assessed.
Results: ThemeanIMTofCCAwashigher in systemic sclerosis patients (right 0.67 ± 0.11 mm, left
0.67 ± 0.12 mm) when compared with the control group (right 0.48 ± 0.2 mm, left 0.54 ± 0.13 mm)
(p< 0.001).Carotid plaqueswere found in 4 SScpatients.Mean IMTwas correlatedwith patients’ age
(p< 0.001), disease duration (p< 0.001), systolic blood pressure (p< 0.05), and dyslipidemia
(p< 0.01). Ankle brachial pressure index (ABPI) was signiﬁcantly lower in SSc patients
(0.94 ± 0.13) when compared with controls (1.16 ± 0.12) (p< 0.001). No difference was found
between limited (n= 25) and diffuse (n= 5) disease subtypes in mean IMT, nor in meanABPI. There
wasno signiﬁcant correlation betweenmean IMTand steroid dose or other immunosuppressive intake.
Conclusion: There is an increased risk of subclinical atherosclerosis andperipheral arterial disease in
SSc patients. Increased systolic blood pressure, dyslipidemia, long disease duration and older age were
possible risk factors.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
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Systemic sclerosis (SSc) is considered as a systemic disease that
mainly affects small vessels. However SSc patients are more
likely to develop peripheral arterial disease (PAD) which is
considered as a kind of macrovascular disease [1]. It is a rheu-
matic disease of unknown etiology characterized by wide-
spread vasculopathy and extracellular matrix deposition
leading to ﬁbrosis and autoimmune processes [2]. Vascular
abnormalities are one of the primary pathologic components
of SSc and recent evidence suggests the presence of anti-angio-
genic factors [3]. Pathological involvement of coronary arteries
in asymptomatic SSc Egyptian patients is not uncommon but
not paralleled by clinical symptomatology [4].
The development of accelerated atherosclerosis in SSc is
less clear, however, an increase in carotid IMT in SSc patients
has been reported [5,6], clinically there is also little evidence for
increased macrovascular complications such as stroke and
myocardial infarction in SSc patients [7].
Carotid intima-media thickness (IMT) as measured by
high-resolution ultrasound is a well-validated marker of sub-
clinical atherosclerosis [8]. The role of duplex scanning in the
investigation of carotid artery disease is well established, and
there is evidence to suggest that it has a predictive role in iden-
tifying those patients with a greater than normal risk of stroke
[5]. The study of the IMT in other rheumatic diseases on Egyp-
tian patients showed subclinical atherosclerosis in rheumatoid
arthritis [9], systemic lupus erythematosus [10], Behc¸ets disease
[11] and primary osteoarthritis [12].
The role of ankle brachial pressure index (ABPI) in predict-
ing cardiovascular mortality is well established [8]. It is used in
the investigation of atherosclerotic peripheral obstructive dis-
ease, with the severity of arterial disease being inversely pro-
portional to the ABPI [6].
The aim of this work is to measure the extent of subclinical
atherosclerosis in patients with systemic sclerosis as well as
peripheral artery disease, and to evaluate any potential vascu-
lar risk factors in these patients.
2. Patients and methods
This study was done on 30 patients with systemic sclerosis
recruited from the Rheumatology and Rehabilitation depart-
ments, Cairo University. The patients fulﬁlled the American
College of Rheumatology (ACR) classiﬁcation criteria for
scleroderma [13] and were further subclassiﬁed to have diffuse
(dcSSc) or limited (lcSSc) cutaneous subset of SSc according to
Le Roy et al. [14]. The exclusion criteria were the presence of
mixed connective tissue disease and other autoimmune connec-
tive tissue pathologies overlapping with SSc.
In addition, 20 healthy individuals with matched age, sex
and BMI to the SSc patients served as the control group. All
patients were assessed clinically and subjected to routine labo-
ratory investigations. Demographic data, smoking status, dis-
ease history (duration, articular, extra-articular and organ
involvements and treatment regimens) and signs of skin, artic-
ular and organ involvement were recorded. Laboratory inves-
tigations included the lipid proﬁle; total cholesterol, high
density lipoprotein (HDL), low density lipoprotein (LDL), tri-
glycerides (TG), and random blood sugar. A non-invasive vas-
cular test ‘carotid duplex scanning’ was performed to measurethe intima media thickness (IMT) of the common carotid
arteries (CCA). The patients’ consents were obtained and the
study was approved by the local ethics committee in accor-
dance to the 1964 Helsinki declaration.
The severity of SSc was assessed by Medsger SSc severity
scale [15]. Clinical examination included a record of the blood
pressure and was followed by measurement of the ankle-bra-
chial pressure index (ABPI); using suitably sized sphygmoma-
nometer to measure the ankle and brachial systolic pressure on
each side and the lower value taken to calculate the ratio of
ankle to brachial systolic pressure.
All patients underwent carotid Doppler ultrasound exami-
nation using Philips HDI 5000 duplex with a 7.5–12 megahertz
linear array, the IMT of CCA was measured 1 cm distal to the
carotid bifurcation in the posterior wall, performed by a skilled
operator. For each patient the highest IMT among the mea-
sured segments studied on each side was recorded. According
to current sonographic criteria IMT was considered ‘‘normal’’
when less than 0.9 mm, ‘‘thickened’’ when IMT was equal to
or more than 0.9 mm and when the thickness was more than
1.3 mm was indicative of atherosclerotic plaque [16].
Statistical analysis: Data were collected and analyzed by
SPSS version 11.0 statistical package, qualitative data were
presented in the form of number and percent and analyzed
by Fisher exact test. Quantitative data were expressed as mean
and standard deviation (±SD) for normally distributed data
and as median and range for non-normally distributed data.
Student’s t-test was used for comparison of the means of two
groups which were normally distributed and Mann–Whitney
U test for non-normally distributed quantitative variable.
Pearson correlation coefﬁcient (r) was used to test the associa-
tion between two quantitative variables. A p-value less than
0.05 was considered statistically signiﬁcant.3. Results
Out of the 30 studied patients, 3 (10%) were males and 27
(90%) were females. Their ages ranged from 19 to 60 years
with a mean age of 42.5 ± 12.38 years. Their disease duration
ranged from 1 to 36 years with a mean duration of
18.5 ± 17.5 years. Their age at disease onset ranged from 17
to 46 years with a mean of 31.5 ± 14.5. Five patients out of
30 (16.7%) had dcSSc and 25/30 (83.3%) had lcSSc. The clin-
ical characteristics, severity score index and laboratory fea-
tures of the studied SSc patients are presented in Table 1.
We found that the measurements of carotid duplex IMT of
SSc patients were signiﬁcantly greater than those of the control
group. However on comparing IMT measurements of carotid
arteries regarding disease subtypes we did not ﬁnd signiﬁcant
difference between diffuse and limited subtypes of the disease
(Tables 2 and 3).
We found that 11 of SSc patients had thickened carotid
artery and the other 19 had not. The mean age and disease
duration and mean systolic blood pressure were found to be
signiﬁcantly higher in SSc patients who had thickened carotid
IMT than those who had not. Also regarding the lipid proﬁle,
the mean total cholesterol, HDL, LDL, and TG levels were
found to be signiﬁcantly higher in SSc patients who had thick-
ened carotid IMT than those who had not. In regard to steroid
intake, use of methotrexate, hydroxychloroquine or vasodila-
tors we did not ﬁnd any signiﬁcant difference between SSc
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who had not (Table 4).
The ankle brachial pressure index (ABPI) measurements in
SSc patients were found to be signiﬁcantly lower than that in
the control group. However no signiﬁcant difference was
found regarding both disease subtypes (Table 5).Table 1 Clinical characteristics, severity score index and
laboratory features of the SSc patients.
Systemic sclerosis (SSc) patients (n= 30)
Clinical manifestation Number (%)
Raynaud’s 30 (100)
Fatigue 28 (93.3)
Weight loss 21 (70)
Cutaneous 19 (63.3)
Arthritis 9 (30)
Arthralgia 26 (86.7)
Tenosynovitis 3 (10)
Myositis 6 (20)
Pulmonary 16 (53.3)
Cardiovascular 7 (23.3)
Hypertension 14 (46.6)
Gastrointestinal 28 (93.3)
Renal 1 (3.3)
Sjo¨grens syndrome 3 (10)
FMS 5 (16.7)
Severity score index Mean ± SD (range)
General 0.70 ± 0.8 (0–2)
Peripheral vascular 1.47 ± 1.4 (0–3)
Skin 1.97 ± 0.8 (1–4)
Joints and tendons 0.87 ± 0.9 (0–3)
Muscles 0.93 ± 0.6 (0–2)
GIT 0.90 ± 1.1 (0–3)
Pulmonary 0.38 ± 0.6 (0–2)
Cardiac 0.23 ± 0.5 (0–2)
Renal 0.07 ± 0.3 (0–1)
Laboratory feature Mean ± SD
Hb (g/dl) 12.3 ± 1.2
WBC (·103/mm3) 8.3 ± 2.2
Platelets (·103/mm3) 303.8 ± 80.7
ESR (mm/1st h) 45.5 ± 26.7
Creatinine (mg/dl) 0.75 ± 0.12
ALT (U/L) 21.1 ± 5.8
RBS (mg/dl) 98.8 ± 12.4
Cholesterol (mg/dl) 187.1 ± 145.9
HDL (mg/dl) 46.4 ± 45.1
LDL (mg/dl) 105.4 ± 19.6
TG (mg/dl) 98.4 ± 43.8
FMS, ﬁbromyalgia syndrome; Hb, hemoglobin; WBC, white blood
cells; ESR, erythrocyte sedimentation rate; ALT, alanine transam-
inase; FBS, fasting blood sugar; HDL, high density lipoprotein;
LDL, low density lipoprotein; TG, triglycerides.
Table 2 Comparison between SSc patients and controls regarding
IMT mean ± SD SSc patients (n= 30)
Rt CCA 0.67 ± 0.11
Lt CCA 0.67 ± 0.12
IMT, intima media thickness; CCA, common carotid artery; S, signiﬁcanOn correlation between carotid artery measurements and
various parameters among SSc patients we found a signiﬁcant
correlation between carotid IMT and age of the patients, dis-
ease duration, systolic blood pressure, LDL, HDL, TG and
total cholesterol levels. However, no signiﬁcant correlation
was found between it and ESR nor with blood sugar level
(Table 6).
4. Discussion
Systemic sclerosis (SSc) is a multisystem autoimmune disease
characterized by vasculopathy and organ ﬁbrosis. Vasculopa-
thy is triggered by endothelial damage, which occurs early in
SSc. Although the detrimental effects of SSc on the small arter-
ies and capillaries are well known, increasing evidence shows
that atherosclerosis is also present in SSc, and the rate of ath-
erosclerosis may be increased in SSc patients compared to
healthy individuals [17].
With this background, we have studied two controversial
issues, the ﬁrst was measuring the extent of subclinical athero-
sclerosis as well as peripheral artery disease in patients with
SSc compared with controls; and the second was to evaluate
any potential vascular risk factors including blood pressure,
blood sugar, lipids (total cholesterol, HDL cholesterol, LDL
cholesterol, and triglycerides), and steroid usage.
The present study showed that the mean IMT of the com-
mon carotid arteries was signiﬁcantly greater in SSc patients
than in the controls. This ﬁnding goes in line with many studies
which reported a signiﬁcant increase in the IMT of common
carotid arteries than in the controls [5,6,17–24].
In contrast to the previous ﬁndings, other studies [25–31]
found that the mean common carotid arteries IMT were not
signiﬁcantly increased compared with healthy controls. The
differences between the results of the present study and the
results of these studies may be due to the larger percentage
of diffuse cutaneous SSc subtype in these studies compared
with ours. Also the mean disease duration in these studies
was less than that of the present study and this may explain
the differences in the ﬁndings.
Regarding disease subtypes, we did not ﬁnd any signiﬁcant
difference in the mean values of common carotid IMT between
limited and diffuse disease subtypes. Our results matched those
of Cheng and colleagues [25], Szucs and coworkers [27], Kalo-
udi and others [28] and Hettema and others [29].
In this study, we correlated IMT of carotid arteries with
some clinical and laboratory parameters in SSc patients includ-
ing age, disease duration, systolic blood pressure, ESR, lipid
proﬁle levels, random blood sugar and ankle brachial pressure
index (ABPI). We found that macrovascular affection in the
form of thickened common carotid IMT in SSc patients corre-
lates positively with the mean age of SSc patients, disease dura-
tion, systolic blood pressure, total cholesterol level and HDL
cholesterol level levels. But there was no signiﬁcant correlationthe CCA IMT.
Controls (n= 20) p Sig.
0.48 ± 0.20 <0.001 S
0.54 ± 0.13 <0.001 S
t.
Table 3 Comparison between lcSS and dcSS subtypes as regards the CCA IMT.
IMT mean ± SD lcSSc (n= 25) dcSSc (n= 5) p Sig.
Rt CCA 0.65 ± 0.11 0.74 ± 0.05 >0.05 NS
Lt CCA 0.67 ± 0.12 0.69 ± 0.12 >0.05 NS
IMT, intima media thickness; CCA, common carotid artery; NS, non signiﬁcant.
Table 4 Comparison between SSc patients with thickened CCA IMT and those without regarding demographic and other risk
factors.
Demographic and other risk factors mean ± SD or n (%) Common carotid artery IMT p Sig.
Thickened (n= 11) Normal (n= 19)
Age (years) 53.6 ± 3.6 36.2 ± 11.1 <0.001 S
Duration of disease (years)
Mean ± SD 18.0 ± 10.5 6.1 ± 5.4 <0.001 S
Median (range) 15 (5–36) 5 (1–24)
Gender
Male 1 (9.1) 2 (10.5) >0.05 NS
Female 10 (90.9) 17 (89.5)
Total 11 (100) 19 (100)
Smoking
Positive 1(9.1) 1 (5.3) >0.05 NS
Negative 10 (90.9) 18 (94.7)
Total 11 (100) 19 (100)
Diabetes
Positive 1 (9.1) 1 (5.3) >0.05 NS
Negative 10 (90.9) 18 (94.7)
Total 11 (100) 19 (100)
Blood pressure
Systolic (mmHg) 134.6 ± 10.4 123.7 ± 12.5 <0.05 S
Diastolic (mmHg) 84.1 ± 7 77.9 ± 9.3 >0.05 NS
Cholesterol (mg/dl) 247.4 ± 46.1 152.2 ± 18.9 <0.001 S
HDL (mg/dl) 50.04 ± 8.4 44.30 ± 2.5 <0.01 S
LDL (mg/dl) 123.6 ± 14.1 94.79 ± 13.6 <0.001 S
TG (mg/dl) 134.5 ± 36.7 77.54 ± 33.02 <0.001 S
Steroid 5 (45.5) 19 (100) >0.05 NS
Methotrexate 7 (63.3) 9 (47.3) >0.05 NS
Hydroxychloroquine 2 (18.2) 11 (57.9) >0.05 NS
Vasodilators 9 (81.8) 5 (26.3) >0.05 NS
IMT, intima media thickness; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglycerides; S, signiﬁcant; NS, non
signiﬁcant.
Table 5 Comparison between SSc patients, control and subtypes as regards the measurement of ABPI.
ABPI mean ± SD SSc patients (n= 30) Controls (n= 20) p Sig.
All patients 0.94 ± 0.13 1.16 ± 0.12 <0.001 NS
Sub types
lcSSc (n= 25) 0.95 ± 0.18
dcSSc (n= 5) 0.9 ± 0.11 >0.05 NS
ABPI, ankle brachial pressure index; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; n, number; NS,
non-signiﬁcant.
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matched those of other studies done by Szucs and colleagues
[27] and Hettema and others [29].Treatment with immunosuppressive agents, especially cor-
ticosteroids, inﬂuences the atherogenic process. Corticoste-
roids are considered to have atherogenic properties, like
Table 6 Correlation between common carotid artery (CCA) IMT measurements and various parameters among SSc patients.
Parameter Rt CCA IMT Lt CCA IMT
R p Sig. R p Sig.
Age (years) 0.68 <0.001 S 0.60 <0.001 S
Disease duration (years) 0.56 <0.001 S 0.52 <0.01 S
Systolic BP (mmHg) 0.54 <0.05 S 0.43 <0.05 S
ABPI 0.2 >0.05 NS 0.17 >0.05 NS
Cholesterol 0.78 <0.001 S 0.62 <0.001 S
HDL 0.52 <0.01 S 0.53 <0.01 S
LDL 0.58 <0.001 S 0.51 <0.01 S
TG 0.67 <0.001 S 0.54 <0.001 S
ESR 0.24 >0.05 NS 0.39 >0.05 NS
RBS 0.30 >0.05 NS 0.11 >0.05 NS
IMT, intima media thickness; BP, blood pressure; ABPI, ankle brachial pressure index; HDL, high density lipoprotein; LDL, low density
lipoprotein; TG, triglycerides; ESR, erythrocyte sedimentation rate; RBS, random blood sugar; S, signiﬁcant; NS, non signiﬁcant.
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trexate, a protective effect against atherosclerosis has been
described [29]. It is difﬁcult to establish whether the
observed association between immunosuppressive agents
and atherosclerosis is due to the immunosuppressive agents
themselves or to their effect on the activity of the autoim-
mune disease.
Regarding drug intake, we did not ﬁnd signiﬁcant differ-
ence between SSc patients with thickened common carotid
IMT and those without regarding steroid intake, methotrexate
or hydroxychloroquine intake. Our results matched those of
Hettema et al. [29], who reported that, no association was
found between common carotid IMT and prednisolone dose
and use of other immunosuppressive agents.
The above results can be explained by that glucocorticoid
treatment increases total cholesterol and HDL cholesterol
more quickly, with a concomitant faster improvement of the
atherogenic index (total cholesterol/HDL ratio) [30]. Cortico-
steroids also decrease the risk of atherosclerosis by controlling
inﬂammation [31–34].
Among the limitations of this study is the small number of
the patients and a larger scale is recommended taking into
consideration a total skin thickness measure. A longitudinal
study design and extended statistical tests including a regres-
sion analysis should be considered to further elucidate the
impact of the risk factors on the development of subclinical
atherosclerosis.
We can conclude that, there is an increased risk of subclin-
ical atherosclerotic macrovascular disease in SSc patients
which is evidenced by increased IMT of common carotid arter-
ies compared with healthy controls. No correlations were
found between IMT and disease related variables including
disease subtypes and severity as assessed by Medsger severity
scale, but a signiﬁcant correlation was displayed with disease
duration, age of the patients and systolic blood pressure. Fur-
ther research is necessary to identify the mechanism of
increased risk of atherosclerosis in SSc and to elucidate the
nature of macrovascular abnormalities and the risk factors
associated with it.
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